Activating Transcription Factor 6 (CT) Blocking Peptide [A275] : Leinco Technologies, excellence in early discovery research

0 $0.00

Product Datasheet

www.leinco.com

excellence in early discovery research

Activating Transcription Factor 6 (CT) Blocking Peptide

(ATF6)

Blocking Peptide

Share |

Size

50 µg ( $115.00 )

Add to Cart:

Prod. No.:	A275
Conc.:	0.2 mg/ml
Pkg. Size:	50 µg
Storage:	-20°C Detailed storage instructions below.

Description

Background:

Activating Transcription Factor 6 peptide is applicable as a control peptide for blocking antibody binding in Western blotting.

Amino Acid Location

16 amino acids near the carboxy terminus of human ATF6.

Formulation

This peptide is formulated in PBS pH 7.2 (0.01 M Sodium Phosphate, 0.13 M NaCl) containing 0.1% bovine serum albumin and 0.02% sodium azide.

Storage and Stability

Store this peptide in working aliquots at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.

Reported Applications

N, WB

Neutralization: The peptide may be used to neutralize the binding activity of Anti-Human Activating Transcription Factor 6 (CT) (ATF6) (Leinco Prod. No.: A271) by incubation of an equal volume of the peptide and antibody for 30 minutes at 37°C for Western blotting experiments.

Each investigator should determine their own optimal working dilution for specific applications.

Country of Origin

USA

References

1. Dillon SR, Sprecher C, Hammond A, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat. Immunol. 2004; 5:752-60.

2. Dreuw A, Radtke S, Pflanz S, et al. Characterization of the signaling capacities of the novel gp130-like cytokine receptor. J. Biol. Chem. 2004; 279:36112-20.

3. Diveu C, Lak-Hal AH, Froger J, et al. Predominant expression of the long isoform of GP130-like (GPL) receptor is required for interleukin-31 signaling. Eur. Cytokine Netw. 2004; 15:291-302.

4. Bilsborough J, Leung DY, Maurer M, et al. IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. J. Allergy Clin. Immunol. 2006; 117:418-25.